Coagulation Calculator Using Logit INR for Warfarin Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing warfarin therapy, particularly in regulating INR levels, suffer from significant variability and fluctuations, leading to increased risks of bleeding and thromboembolism due to inadequate dosing control, despite existing algorithms and computer models that fail to accurately predict and stabilize anticoagulation levels.
Innovation Solution
A dose-response relationship for Vitamin K antagonists and Vitamin K is established, allowing for numerical computation of initial and ongoing dosing, with a coagulation calculator using logit(1/INR) as a dependent variable to calculate optimal dosages and predict INR adjustments, stabilizing anticoagulation status through patient-specific parameter estimation and high-frequency dose oscillation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional INR monitoring and dosing adjustment methods are used, then warfarin therapy can be administered, but significant INR variability and fluctuations occur leading to increased bleeding and thromboembolism risks
Solution Approach 1:
The patent implements a feedback mechanism where INR measurements are continuously monitored and fed back to adjust warfarin dosing. The system uses recent INR values to dynamically calculate optimal dosing adjustments, creating a closed-loop control system that responds to actual patient coagulation status rather than relying on fixed dosing schedules.
Solution Approach 2:
The dosing algorithm transitions from static, fixed dosing schedules to dynamic, adaptive dosing. The system continuously adjusts the recommended dose based on the most recent INR measurement and patient-specific parameters, allowing the dosing regimen to evolve and adapt to changing patient conditions and warfarin sensitivity.
2Ease of operation
If existing dosing algorithms and computer models are used, then dosing recommendations can be provided, but they fail to accurately predict and stabilize anticoagulation levels
Solution Approach 1:
The patent transforms the INR parameter through logarithmic transformation (log(INR)) to linearize the dose-response relationship. This parameter transformation allows the system to model the nonlinear relationship between warfarin dose and INR using linear regression techniques, improving prediction accuracy while maintaining computational simplicity.
Solution Approach 2:
The system automatically estimates patient-specific parameters (warfarin sensitivity and baseline INR) from historical INR and dosing data without requiring manual input. The algorithm self-calibrates by analyzing the patient's response to previous dose changes, eliminating the need for physician manual calibration and enabling accurate predictions from the outset.
3Reliability
If warfarin dosing is increased to reduce thromboembolism risk, then anticoagulation effect is enhanced, but bleeding risk increases due to excessive INR elevation
Solution Approach 1:
The feedback mechanism monitors INR levels and automatically adjusts dosing to maintain INR within the therapeutic range. When INR approaches the upper limit, the system reduces or pauses dosing to prevent excessive anticoagulation and bleeding, while maintaining sufficient anticoagulation to prevent thromboembolism.
Solution Approach 2:
The system uses conservative dosing adjustments that account for the delayed effect of warfarin on INR. Rather than making aggressive dose changes, the algorithm applies partial adjustments that prevent over-correction and allow the system to gradually approach the target INR range, reducing the risk of oscillations and excessive anticoagulation.
4Object-affected harmful factors
If warfarin dosing is decreased to reduce bleeding risk, then safety is improved, but thromboembolism protection is compromised due to insufficient INR elevation
Solution Approach 1:
The feedback system continuously monitors INR levels and adjusts dosing to maintain the therapeutic balance. When INR falls below the target range, the system increases dosing to restore adequate anticoagulation protection, ensuring that safety measures do not compromise thromboembolism prevention.
Solution Approach 2:
The dynamic dosing algorithm adapts to patient-specific warfarin sensitivity, automatically calculating the precise dose needed to achieve target INR. This eliminates the need for conservative under-dosing, as the system precisely tailors the dose to individual patient requirements, maintaining both safety and efficacy.
Data Source
AI summary
Contemplated methods and devices for coagulation control allow to establish a more constant dosage of required medication and to quantify/take into account patient-specific sensitivity to warfarin and Vitamin K by using logit (1/INR) as the dependent variable to so stabilize the variance across all values of INR. Moreover, it should be noted that such use simplifies the relation between INR and dose of coumarins or Vitamin K and reduces the number of parameters to be estimated for each patient.